DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) — MannKind Company MNKD, an organization targeted on the event and commercialization of revolutionary inhaled therapeutic merchandise and gadgets for sufferers with endocrine and orphan lung illnesses, introduced in the present day that Chief Govt Officer Michael Castagna, PharmD, and Chief Monetary Officer Chris Prentiss will share updates throughout a fireplace chat on the 2024 UBS Healthcare Convention in Rancho Palos Verdes, Calif.
The hearth chat will happen on Tuesday, November 12, at 10:15 a.m. Pacific Time. A hyperlink to the reside audio webcast of the session might be out there on MannKind Company’s web site at: https://investors.mannkindcorp.com/events-and-presentations. A recorded model can even be out there on the web site for about 30 days following the convention.
About MannKind
MannKind Company MNKD focuses on the event and commercialization of revolutionary inhaled therapeutic merchandise and gadgets to deal with critical unmet medical wants for these residing with endocrine and orphan lung illnesses.
We’re dedicated to utilizing our formulation capabilities and system engineering prowess to reduce the burden of illnesses comparable to diabetes, nontuberculous mycobacterial (NTM) lung illness, pulmonary fibrosis, and pulmonary hypertension. Our signature applied sciences – dry-powder formulations and inhalation gadgets – supply fast and handy supply of medicines to the deep lung the place they will exert an impact domestically or enter the systemic circulation, relying on the goal indication.
With a passionate group of Mannitarians collaborating nationwide, we’re on a mission to offer individuals management of their well being and the liberty to reside life.
Please go to mannkindcorp.com to study extra, and comply with us on LinkedIn, Facebook, X or Instagram.
This press launch was revealed by a CLEAR® Verified particular person.
For MannKind: Investor Relations Ana Kapor (818) 661-5000 E-mail: [email protected] Media Relations Christie Iacangelo (818) 292-3500 E-mail: [email protected]
Market Information and Knowledge delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
